Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Development and Validation of a Highly Sensitive e1a2 (p190) BCR-ABL Test to Determine Complete Molecular Response (Minimal Residual Disease Negative) As a Primary Endpoint for Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Kristy Drafahl, David C Smith, Cristen Graham, Christine Glynn, Cindy Spittle, Scott Verrow, Victor M. Rivera, PhD, Shouryadeep Srivastava, MBBS, PhD, Kevin Hawkins, Chad Galderisi, DO

Blood (2018) 132 (Supplement 1): 1558.

https://doi.org/10.1182/blood-2018-99-113172

Published: 2018

Journal Articles

Development and Validation Of Highly Sensitive Mrdx BCR-ABL Test For Monitoring Deep Molecular Response In Patients With Chronic Myeloid Leukemia

Julie Toplin, Kristy Drafahl, Jonathan Eibl, Clark Fjeld, Thomas Yager, Staci McAdams, Kevin Hawkins, Chad Galderisi

Blood (2013) 122 (21): 2617.

https://doi.org/10.1182/blood.V122.21.2617.2617

Published: 2013

Journal Articles

Phasing Analysis Of TKI Resistance Mutations In The BCR-ABL1 Kinase Domain and Neighboring Domains Using Next-Generation Sequencing

Jin Li, Zhenyu Yan, Agus Darwanto, Peng Fang, Weihua Liu, Kristy Drafahl, Julie Toplin, Cindy Spittle, Chad Galderisi

Blood (2013) 122 (21): 3817.

https://doi.org/10.1182/blood.V122.21.3817.3817

Published: 2013

Journal Articles

Next-Generation Sequencing of the BCR-ABL1 Kinase Domain and Neighboring Domains Associated with Therapy Resistance.

Jin Li, Weihua Liu, Zhenyu Yan, Peng Fang, Agus Darwanto, Kim Pelak, Julie Toplin, Kim Anoe, Cindy Spittle, Chad Galderisi, Stephane Wong

Blood (2012) 120 (21): 2549.

https://doi.org/10.1182/blood.V120.21.2549.2549

Published: 2012

Journal Articles

An MMR Control RNA for Reliable Monitoring of BCR-ABL Transcripts in Treated CML Patients.

Julie Toplin, Courtney Fuller, Linda Fletcher, Stephane Wong, Peter Maslak, Jorge Cortes, Rosemary Mazanet, Susan Branford, Timothy Hughes, Chad Galderisi, Michael Heinrich, Brian Druker, Emmanuel Beillard

Blood (2007) 110 (11): 2939.

https://doi.org/10.1182/blood.V110.11.2939.2939

Published: 2007

NARROW

Development and Validation of a Highly Sensitive e1a2 (p190) BCR-ABL Test to Determine Complete Molecular Response (Minimal Residual Disease Negative) As a Primary Endpoint for Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Development and Validation Of Highly Sensitive Mrdx BCR-ABL Test For Monitoring Deep Molecular Response In Patients With Chronic Myeloid Leukemia

Phasing Analysis Of TKI Resistance Mutations In The BCR-ABL1 Kinase Domain and Neighboring Domains Using Next-Generation Sequencing

Next-Generation Sequencing of the BCR-ABL1 Kinase Domain and Neighboring Domains Associated with Therapy Resistance.

An MMR Control RNA for Reliable Monitoring of BCR-ABL Transcripts in Treated CML Patients.

Email alerts

ASH Publications

American Society of Hematology

Development and Validation of a Highly Sensitive e1a2 (p190) BCR-ABL Test to Determine Complete Molecular Response (Minimal Residual Disease Negative) As a Primary Endpoint for Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Development and Validation Of Highly Sensitive Mrdx BCR-ABL Test For Monitoring Deep Molecular Response In Patients With Chronic Myeloid Leukemia

Phasing Analysis Of TKI Resistance Mutations In The BCR-ABL1 Kinase Domain and Neighboring Domains Using Next-Generation Sequencing

Next-Generation Sequencing of the BCR-ABL1 Kinase Domain and Neighboring Domains Associated with Therapy Resistance.

An MMR Control RNA for Reliable Monitoring of BCR-ABL Transcripts in Treated CML Patients.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only